Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
FV Supplement Ltd is a healthcare company founded by Dr. Owusu Akyiaw Bempah that focuses on the treatment and prevention of chronic diabetes complications. The company's primary product, Fenomin, is a specialized formulation of B-vitamins (thiamine, nicotinamide, and calcium pantothenate) designed to address the "polyuria paradigm" of diabetes. According to the company's research, chronic polyuria in diabetic patients leads to a critical deficiency of these vitamins in the blood plasma, which in turn causes organ damage. Fenomin aims to restore these levels and activate the transketolase enzyme to prevent and reverse early-stage complications such as retinopathy, nephropathy, and diabetic foot ulcers. Although the company's UK-registered entity was dissolved in 2020, its research and products continue to be promoted through its operations in Ghana and academic publications.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on fv Supplement.